SE521049C2 - Farmaceutiska kompositioner för förhindrande och behandling av cancerösa sjukdomar samt process för beredning av dessa - Google Patents

Farmaceutiska kompositioner för förhindrande och behandling av cancerösa sjukdomar samt process för beredning av dessa

Info

Publication number
SE521049C2
SE521049C2 SE9502474A SE9502474A SE521049C2 SE 521049 C2 SE521049 C2 SE 521049C2 SE 9502474 A SE9502474 A SE 9502474A SE 9502474 A SE9502474 A SE 9502474A SE 521049 C2 SE521049 C2 SE 521049C2
Authority
SE
Sweden
Prior art keywords
weight
acid
composition
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
SE9502474A
Other languages
English (en)
Swedish (sv)
Other versions
SE9502474D0 (sv
SE9502474L (sv
Inventor
Gyula Kulcsar
Original Assignee
Immunal Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunal Kft filed Critical Immunal Kft
Publication of SE9502474D0 publication Critical patent/SE9502474D0/xx
Publication of SE9502474L publication Critical patent/SE9502474L/xx
Publication of SE521049C2 publication Critical patent/SE521049C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
SE9502474A 1993-11-09 1995-07-06 Farmaceutiska kompositioner för förhindrande och behandling av cancerösa sjukdomar samt process för beredning av dessa SE521049C2 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9303171A HU213677B (en) 1993-11-09 1993-11-09 Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them
PCT/HU1994/000049 WO1995013061A1 (en) 1993-11-09 1994-11-08 Pharmaceutical compositions for prevention and treatment of cancerous disease and process for their preparation

Publications (3)

Publication Number Publication Date
SE9502474D0 SE9502474D0 (sv) 1995-07-06
SE9502474L SE9502474L (sv) 1995-07-06
SE521049C2 true SE521049C2 (sv) 2003-09-23

Family

ID=10984131

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9502474A SE521049C2 (sv) 1993-11-09 1995-07-06 Farmaceutiska kompositioner för förhindrande och behandling av cancerösa sjukdomar samt process för beredning av dessa

Country Status (18)

Country Link
EP (1) EP0679081B1 (de)
JP (1) JPH08508045A (de)
KR (1) KR100363779B1 (de)
CN (1) CN1128615C (de)
AT (1) AT408414B (de)
AU (1) AU682735B2 (de)
CA (1) CA2151826C (de)
CH (1) CH686867A5 (de)
CZ (1) CZ286633B6 (de)
DE (2) DE69429806T2 (de)
ES (1) ES2094702B1 (de)
FI (1) FI953369A7 (de)
HU (1) HU213677B (de)
NL (1) NL195007C (de)
PL (1) PL177981B1 (de)
RU (1) RU2138257C1 (de)
SE (1) SE521049C2 (de)
WO (1) WO1995013061A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5864024A (en) * 1994-07-11 1999-01-26 Glinskii; Guennadi Victor Synthetic glycoamines and methods for their use that affect cell adhesion, inhibit cancer cell metastasis, and induce apoptosis
EP0967984A1 (de) * 1997-03-04 2000-01-05 Peregrine Pharmaceutical, Inc. Zusammensetzung und verfahren zur behandlung von krebs und immunkrankheiten, die in chronische erkrankungen resultieren
RU2108786C1 (ru) * 1997-09-15 1998-04-20 Клавдия Степановна Евланенкова Средство для лечения онкологических больных
US6284786B1 (en) 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
IT1312060B1 (it) * 1999-04-09 2002-04-04 Antibioticos Spa Uso dell'acido alfa lipoico nel trattamento antimetastatico.
ES2164013B1 (es) * 2000-04-14 2003-06-16 Consejo Superior Investigacion Glicosidos de n-acetil-6-o-(2,2-bis(hidroximetil)-3-hidroxipropil)-d-glucosamina, procedimiento de obtencion y uso en el tratamiento de tumores cerebrales.
KR100465229B1 (ko) * 2001-04-09 2005-01-13 주식회사 안지오랩 2-아미노-2-데옥시-ｄ-글루코피라노오즈 또는 그의약학적으로 허용가능한 염을 유효성분으로 하는 혈관신생억제용 약학적 조성물
RU2188458C2 (ru) * 2001-07-24 2002-08-27 Ростовский научно-исследовательский онкологический институт Способ определения дозы этанола в эксперименте для инъекционной терапии опухолей печени
WO2003030890A1 (fr) * 2001-10-05 2003-04-17 Tetsuro Asao Activateurs du systeme immunitaire
EP1583543A4 (de) * 2002-01-16 2009-09-09 Eliezer Rapaport Verfahren und therapeutische zusammensetzungen bei der behandlung fortgeschrittener karzinome
RU2232027C2 (ru) * 2002-10-07 2004-07-10 Новосибирская государственная медицинская академия Способ лечения псевдоэрозии шейки матки с использованием локорегионарной цитокинотерапии
RU2245143C2 (ru) * 2002-12-27 2005-01-27 Хохлов Александр Петрович Аминокислотный препарат, обладающий противоопухолевым действием, и способ его получения
RU2361583C2 (ru) * 2003-10-03 2009-07-20 Вейлен Н.В. Применение соединений, способных повышать уровень igf-1 в сыворотке крови, при приготовлении терапевтической композиции для лечения стадий различных заболеваний, ассоциированных со снижением уровня igf-1 в сыворотке людей и животных
JP5268362B2 (ja) * 2004-12-17 2013-08-21 アラン ビー． キャッシュ 寿命を拡大させ、かつ加齢関連疾患の発症を遅らせるための方法
EP1909804B1 (de) * 2005-08-03 2012-02-29 National Cancer Center Glucosamin und derivate davon als transglutaminase-inhibitoren zur verwendung in der behandlung von einer funktionsstörung des nervensystems
KR100878585B1 (ko) * 2006-06-16 2009-01-15 국립암센터 글루코사민, 글루코사민 유도체 또는 이들의 염을 포함하는항암감작제
KR100780868B1 (ko) * 2006-07-10 2007-11-30 부경대학교 산학협력단 항암효과를 나타내는 4급 아미노 글루코사민 화합물
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
WO2015137383A1 (ja) * 2014-03-11 2015-09-17 味の素株式会社 癌化学療法の補助剤
CN110870914A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 氨基酸类营养素的应用以及包含它的药物组合物
RU2707554C1 (ru) * 2019-02-27 2019-11-28 Федеральное государственное бюджетное учреждение "Петербургский институт ядерной физики им. Б.П. Константинова Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт-ПИЯФ") Композиция, ингибирующая рост и выживаемость опухолевых клеток

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB931921A (en) * 1960-12-22 1963-07-24 Lab Roques Therapeutic compositions intended for the treatment of any hepatic malfunctionings
DE2021969A1 (de) * 1970-04-29 1971-11-18 Boettger Kg Pharmazeutische Un Verfahren zur Herstellung eiweissfreier Praeparate
FR2201879B2 (de) * 1972-05-19 1976-01-23 Tixier Georges Fr
FR2244468A1 (en) * 1973-07-31 1975-04-18 Passwater Richard Anticarcinogenic food supplements - contg antioxidants and S-contg amino acids
JPS5535049A (en) * 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
US4880918A (en) * 1982-07-13 1989-11-14 Eliezer Rapaport Arrest and killing of tumor cells by adenosine 5-diphosphate and adenosine-5-triphosphate
US4935450A (en) * 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
US4647453A (en) * 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
DE3440090A1 (de) * 1984-11-02 1986-05-07 Novo-Med AG, Appenzell Aminosaeureloesungen enthaltendes arzneimittel zur therapie von krebserkrankungen und verfahren zu seiner herstellung
DE3672950D1 (de) * 1985-10-23 1990-08-30 Mulli Kurt Nachf Gmbh Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
DE3821043A1 (de) * 1988-06-22 1989-12-28 Fresenius Ag Dialysier- und spuel-loesung zur intraperitonealen verabreichung
US5214065A (en) * 1990-06-11 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Dc-89 derivatives
KR0172193B1 (ko) * 1991-10-07 1999-02-01 오오쓰까 아끼히꼬 암 치료용 경장제제
US5780039A (en) * 1992-04-23 1998-07-14 Novartis Nutrition Ag Orally-ingestible nutrition compositions having improved palatability
RU2061480C1 (ru) * 1992-06-26 1996-06-10 Нонна Дмитриевна Кислякова Противоопухолевое средство (варианты)

Also Published As

Publication number Publication date
FI953369A7 (fi) 1995-09-06
AU682735B2 (en) 1997-10-16
CA2151826A1 (en) 1995-05-18
HU213677B (en) 1997-12-29
CH686867A5 (de) 1996-07-31
KR100363779B1 (ko) 2003-03-06
DE69429806D1 (de) 2002-03-21
EP0679081B1 (de) 2002-02-06
CN1116406A (zh) 1996-02-07
CN1128615C (zh) 2003-11-26
PL177981B1 (pl) 2000-02-29
HU9303171D0 (en) 1994-01-28
JPH08508045A (ja) 1996-08-27
DE69429806T2 (de) 2002-09-12
WO1995013061A1 (en) 1995-05-18
FI953369L (fi) 1995-07-07
AU1074995A (en) 1995-05-29
CZ177395A3 (en) 1996-01-17
SE9502474D0 (sv) 1995-07-06
DE4498692T1 (de) 1996-02-22
CA2151826C (en) 2008-06-17
FI953369A0 (fi) 1995-07-07
ES2094702A1 (es) 1997-01-16
SE9502474L (sv) 1995-07-06
AT408414B (de) 2001-11-26
NL9420013A (nl) 1995-10-02
NL195007C (nl) 2003-06-10
ATA900894A (de) 2001-04-15
PL309600A1 (en) 1995-10-30
CZ286633B6 (cs) 2000-05-17
ES2094702B1 (es) 1998-02-16
EP0679081A1 (de) 1995-11-02
RU2138257C1 (ru) 1999-09-27

Similar Documents

Publication Publication Date Title
SE521049C2 (sv) Farmaceutiska kompositioner för förhindrande och behandling av cancerösa sjukdomar samt process för beredning av dessa
US6075031A (en) Use of creatine analogues and creatine kinase modulators for the prevention and treatment of glucose metabolic disorders
US12178792B2 (en) Pharmaceutical composition and use thereof in preparing drug for treating tumor multi-drug resistance
JP2002537253A (ja) 癌治療におけるリポ酸のアスコルビン酸との併用
US20040116390A1 (en) Use of creatine analogues and creatine kinase modulators for the prevention and treatment of obesity and its related disorders
AU618997B2 (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer
WO1994016687A1 (en) Use of creatine or analogs for the manufacture of a medicament for inhibiting tumor growth
KR100322404B1 (ko) 간재생용치료제
JP2951407B2 (ja) チアゾフリン及びリバビリンを用いる新生物病の処置方法
CA2320556A1 (en) N,n-dichlorinated omega amino acids and uses thereof
KR20040078123A (ko) 에포틸론 및 대사길항물질을 포함하는 조합물
CN102292081B (zh) 包含硫辛酸和羟基柠檬酸作为活性成分的药物联用物
US20180022734A1 (en) Sunitinib prodrug and pharmaceutical composition
US11957701B2 (en) Therapy and new therapeutic agent for blood cancer
EP1485090B1 (de) Kombinationspräparat aus epothilone derivate und imidazotetrazinone
CN109846876B (zh) 木脂素类化合物在抗肿瘤中的应用及其药物制备
CN115813919B (zh) 吲哚-3-丙酮酸或其药用盐在制备治疗乳腺癌药物中的应用
CN121550252A (zh) 双二羧酸二氨络铂抗癌药物
JPS59112919A (ja) 細胞静止作用を有する協力効果組成物
CN119454969A (zh) 含pd-l1小分子抑制剂的药物组合及其应用
CN121265624A (zh) 金黄霉素a衍生物ca3在治疗白血病方面的用途
CN119015281A (zh) 一种苯甲酰胺类化合物防治恶性肿瘤恶病质的用途
CN111166868A (zh) 一种用于治疗神经疾病和障碍的组合物
JPS59184124A (ja) 腎不全、糖尿病及び糖尿病性腎症におけるエネルギー代謝改善剤
JPS621371B2 (de)

Legal Events

Date Code Title Description
NUG Patent has lapsed